Overview

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Status:
Recruiting

Trial end date:
2023-04-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and tolerability, efficacy, and biomarker response of BMS-986165 administered orally in participants with moderate to severe ulcerative colitis

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

BMS-986165